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Abstract
Background: Oral lichen planus (OLP) decreases the quality of life because it can cause spontaneous pain during
eating and tooth-brushing and an uncomfortable feeling in the mouth. In addition, OLP may be associated with
HCV-related liver disease.
We investigated the visual analogue scale (VAS) and effects of oral care gel, REFRECARE-H
®, on patients with OLP
associated with HCV infection.
Results: Nine OLP patients (mean age 67.9 ± 7.6 years) with HCV-related liver diseases were recruited and their
VAS score determined along with a biochemical examination of the blood. Types of OLP included erosive (6
patients) and reticular (3). REFRECARE-H
®, an oral care gel (therapeutic dentifrice) containing hinokitiol, was applied
by each patient as a thin layer on the oral membrane, after each meal and at bedtime for 30 days. Application of
REFRECARE-H
® improved the quality of life in all terms of dry mouth, breath odor, oral freshness, oral pain during
rest, oral pain at a mealtimes, taste disorder, loss of appetite, sleep disorder, depressive mood and jitteriness. VAS
scores of dry mouth, breath odor, oral freshness, and sleep disorder were significantly increased 30 days after
application of REFRECARE-H
® (P = 0.01, P = 0.05, P = 0.03, P = 0.04). VAS scores of oral pain at a mealtimes and
taste disorder were increased 30 days after application of REFRECARE-H
® (P = 0.06). There was an absence of side
effects.
Conclusions: REFRECARE-H
® improved the quality of life for OLP. It is necessary for the hepatologist to educate
patients regarding oral hygiene, as well as provide treatment of liver disease.
Background
There are 170 million chronic hepatitis C virus (HCV)
carriers throughout the world, of whom an estimated
two million are in Japan. HCV is the major cause of
hepatocellular carcinoma (HCC) in Japan, with 70% of
cases being HCV-related [1]. In addition to Japan, the
number of patients with HCV-related HCC is increasing
worldwide [1].
HCV is associated with a broad spectrum of clinical
and biological extrahepatic manifestations [2]. Chronic
HCV infection has been linked to lichen planus, particu-
larly with the involvement of the oral cavity [3]. Lichen
planus is common among HCV-infected patients in
Japan [4]. According to our studies, about 20% of
patients infected with HCV may develop lichen panus
[4]. The erosive type of oral lichen planus (OLP), in par-
ticular, can cause spontaneous pain during eating and
tooth-brushing or an uncomfortable feeling in the
mouth.
There are several reports of the coexistence of HCV
infection with Sjögren’s syndrome [5,6]. According to
our research, 54 of 531 (10.2%) HCV-infected patients
had a salivary flow below the normal value [7]. Patients
with Sjögren’s syndrome have an increased risk of peri-
odontitis and candidiasis [8].
On April 1, 2008, EN Otsuka Pharmaceutical Co. Ltd.
(Iwate, Japan) released REFRECARE-H
®.R E F R E C A R E -
H
® is an oral care gel (therapeutic dentifrice) containing
hinokitiol which can remove stains on the teeth and
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breath odor and gum diseases (periodontal infection and
gingival inflammation). Hinokitiol is a natural chemical
compound found in the wood of trees of the family
Cupressaceae. Hinokitiol has significant antimicrobial
efficacy against Staphylococcus aureus, Propionibacter-
ium acnes, coronavirus, Trichophyton, and Candida
albicans [9-11].
There are few reports showing that the lesions or
symptoms of OLP decrease the quality of life for OLP
patients with HCV-related liver disease [12]. The visual
analogue scale (VAS) is a simple and frequently used
method for evaluating variations in pain intensity [13].
In this study, we investigated the VAS and effects of
REFRECARE-H
® on patients with OLP associated with
HCV infection.
Material and methods
Subjects
This study included nine Japanese patients (4 males and
5 females) with OLP who were positive for HCV anti-
body (anti-HCV) and who visited our clinic at the Kur-
u m eU n i v e r s i t yH o s p i t a li nJ a p a nf r o mN o v e m b e r2 ,
2011 to November 16, 2011. The patients ranged in age
from 55 to 76 years, with an average age of 67.9 ± 7.6
years.
The biopsy specimens from all subjects showed histo-
logic features characteristic of OLP. The types of OLP
included erosive (6 patients) and reticular (3). All
patients had been treated with topical administration of
steroids and by elimination of irritating factors, for
example, bad fillings and ill-fitting dentures.
Serological assays
Sera from all nine patients were evaluated for white
blood cell counts (WBC), red blood cell counts (RBC),
hemoglobin (Hb) and platelets (PLT) and the following
liver function tests were carried out: aspartate amino-
transferase (AST), alanine aminotransferase (ALT),
gamma-glutamyl transpeptidase (g-GTP), alkaline phos-
phatase (ALP), lactate dehydrogenase (LDH), albumin
(Alb), total bilirubin (T.Bil), and creatinine. The blood
levels of hemoglobin A1c (HbA1c) and fasting blood
glucose (FBS) were measured. Ultrasonographic exami-
nation was performed for all patients in order to investi-
gate the shape of the liver and lesions occupying the
liver. Computed tomography and liver biopsy were per-
formed in some patients.
Design of the administration of REFRECARE-H
®
REFRECARE-H
®, an oral care gel (therapeutic denti-
frice) including hinokitiol, was applied by each patient
as a thin layer on the oral membrane, after each meal
and at bedtime for 30 days.
Informed consent according to Helsinki Declaration II
for participation in the study was obtained from each
patient.
Salivary flow
We used a simple and low-cost test for detection of xer-
ostomia and this required chewing on a piece of gauze
for 2 min. A salivary flow rate ≤ 2 g/2 min was judged
as decreased salivary secretion.
Evaluation of VAS
A VAS is a horizontal line, 100 millimeters in length,
anchored by word descriptors at each end, as illustrated
in Figure 1. The patients marked on the line the point
that they felt represented their perception of their cur-
rent state, such as dry mouth, breath odor, oral fresh-
ness, oral pain during rest, oral pain at a mealtimes,
taste disorder, loss of appetite, sleep disorder, depressive
mood and jitteriness. The VAS score was determined by
measuring in millimeters from the left hand end of the
line to the point that the patient had marked.
1
Patient Name: Date:
2
Dry mouth
Not at all Very much
Not at all Very much
3
4
5
6
7
8
9
10
Breath odor
Oral freshness
Not at all Very much
Not at all
Not at all
Not at all
Not at all
Not at all
Not at all
Not at all
Very much
Very much
Very much
Very much
Very much
Very much
Very much
Oral pain during rest
Oral pain at a mealtimes
Taste disorder
Loss of appetite
Sleep disorder
Depressive mood
Jitteriness
Figure 1 VAS of 10 items. A VAS is a horizontal line, 100
millimeters in length, anchored by word descriptors at each end.
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All data are expressed as mean ± standard error. Statis-
tical comparisons before application of the REFRE-
CARE-H
® and after 30 days were made using
Wilcoxon’s test. All statistical analyses were carried out
using JMP Version 6 (SAS Institute, Cary, NC, USA).
The level of statistical significance was defined as 0.05.
Results
The characteristics of the nine patients studied are
shown in Table 1. The diagnosis of liver disease
included: chronic hepatitis C (n = 7), liver cirrhosis
and post-treatment of HCC (n = 1), and post inter-
feron (IFN) treatment for chronic hepatitis C (n = 1).
Concomitant medical complications included: hyper-
t e n s i o n( n=5 ) ,d i a b e t e sm e l l i t u s( D M ) ( n=1 )a n d
asthma (n = 1).
The distributions of VAS score before and after appli-
cation of REFRECARE-H
® are as shown in Table 2.
Each VAS score was lower after application of REFRE-
CARE-H
® than before its use. Therefore, application of
REFRECARE-H
® improved the quality of life according
to all criteria. Subjective evaluations of dry mouth,
breath odor, oral freshness and sleep disorders signifi-
cantly improved 30 days after the application of REFRE-
CARE-H
® (P = 0.01, P = 0.05, P = 0.03, P = 0.04, Table
2). Subjective evaluations of oral pain at a mealtimes
and taste disorder improved 30 days after the applica-
tion of REFRECARE-H
® (P = 0.06, Table 2).
We analyzed any changes in laboratory data before
and after the application of REFRECARE-H
® (Table 2).
There were no changes.
Discussion
OLP is characterized by chronic inflammation and is
often associated with severe pain and a burning sensa-
tion in the mouth. In particular, chronic erosive OLP is
a painful disease inducing severe disability with weight
loss and poor quality of life. López-Jornet reported that
the quality of life in Spanish patients with OLP is
reduced and that patient-centered measures should be
considered in the management of OLP [12].
Oral Candida albicans also may be isolated from
patients with OLP. Some Candida albicans isolates with
special virulence attributes might be co-factors which
contribute to the development of OLP, especially erosive
OLP [14]. REFRECARE-H
®, an oral care gel with effi-
cacy against Candida albicans, improved the quality of
life for OLP patients. Therefore, it is a useful agent for
improvement of subjective complaints.
We previously reported that sensitivity to tastes and
zinc levels are decreased in patients with HCV-asso-
ciated liver disease [15]. Some patients had decreased
sensitivity of taste despite the fact that they were una-
ware of their taste disorder. In addition, poor oral health
has been reported for HCV-infected patients [16-19]. In
our previous study, dental problems delayed the initia-
tion of IFN therapy for a maximum of 105 days [7].
HCV-infected patients treated with IFN therapy should
be managed by intensive oral care because of lower
resistance to infection during the therapy. With regard
to the painful OLP, it is just conceivable that an oral
cavity with HCV infection is likely to become less
healthy than one without HCV infection. It is necessary
for a hepatologist to educate patients regarding oral
Table 1 Characteristics of nine OLP patients with HCV-related liver diseases
N0. Age Sex Oral disease Liver disease Concomitant medical complications
1 73 M OLP of bilateral buccal mucosa and lower lip CH-C Hypertension
2 55 M OLP of bilateral buccal mucosa, lower lip, and tongue CH-C DM
3 56 F OLP of bilateral buccal mucosa and tongue CH-C
4 73 F OLP of bilateral buccal mucosa and tongue CH-C Asthma
5 69 F OLP of bilateral palatal plate CH-C Hypertension
6 74 M OLP of tongue CH-C post IFN SVR Hypertension
Post right tongue carcinoma
7 76 F OLP of bilateral buccal mucosa LC-C Hypertension
Sjögren’s syndrome post-treatment of HCC
8 67 F OLP of right buccal mucosa CH-C
9 68 M OLP of lower lip CH-C Hypertension
OLP: oral lichen planus
CH-C: chronic hepatitis type C
LC-C: liver cirrhosis type C
HCC: hepatocellular carcinoma
DM: diabetes mellitus
IFN: interferon
SVR: sustained virologic response
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that the quality of life of patients with HCV-related liver
disease does not decrease. Just as important as the
apparent effectiveness of care using REFRECARE-H
® is
the lack of side effects.
Conclusions
I nc o n c l u s i o n ,w es h o w e dt h a to r a lc a r eg e li m p r o v e d
the subjective symptoms of all patients with OLP. The
results of this study indicate that the use of REFRE-
CARE-H
® could be effective in reducing the subjective
symptoms and quality of life of patients with OLP.
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